Covidien Plans To Bring Back Recalled Duet TRS Surgical Stapling System
This article was originally published in The Gray Sheet
Executive Summary
Covidien’s CEO says the company is trying to bring its surgical stapling system, which was recalled in 2012 after it was linked to postoperative injuries, back to market in about a year.
You may also be interested in...
Covidien Completes Pharma Spinoff, Hears From Tyco On Tax Matter
Covidien is now a $9.9 billion, pure-play medical device and supplies company. Separately, the firm could be liable for more than $1 billion in back taxes due to an IRS audit of its former parent, Tyco, though the case is expected to take years to play out in court.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.